The sheer size of the Fairmount sale ($399.7M, ~5.2% of market cap) is a strong bearish signal, but its interpretation depends on whether Fairmount is a strategic holder or a fund with a concentrated position. Monitor for any 13D filing or press release explaining the sale. If Fairmount is exiting entirely, expect further selling pressure. The CFO's small sale ($436K) is routine post-exercise and less informative.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $90.16entry
- T+1 · 5mo ago −1.53%α −2.31% · $88.78
- T+5 · 4mo ago −1.57%α −2.96% · $88.74
- T+20 · 4mo ago +13.28%α +13.56% · $102.13
- T+60 · 8w ago +2.01%α −2.38% · $91.97
Price Chart
How similar events traded
Executive Summary
A massive insider selling cluster at Spyre Therapeutics (SYRE) saw $402M in open-market sales over four days, led by director Fairmount Funds Management LLC liquidating 4.68M shares ($399.7M) at $85.31. CFO Scott Burrows also sold $436K after exercising options, and director Michael Henderson sold $2M at $100. The $402M total represents ~5.2% of SYRE's $7.7B market cap, a highly material signal, though the dominant seller (Fairmount) is a fund director whose sale may reflect portfolio rebalancing rather than company-specific bearishness.
Key Financial Metrics
Key Facts
- Total insider sales of $402.09M over 4 days, representing ~5.2% of SYRE's $7.7B market cap
- Fairmount Funds Management LLC (Director) sold 4,684,781 shares at $85.31 for $399.66M on 2026-06-23
- CFO Scott Burrows sold 5,000 shares at $87.12 for $435,600 on 2026-06-25 after exercising options
- Director Michael Henderson sold 20,000 shares at $100.00 for $2.00M on 2026-06-22
- No open-market purchases in the cluster; all cash transactions were sales
- Recent 30-day insider activity shows $402.7M in total sales, nearly all from this cluster
Financial Impact
Insider sales of $402.09M represent ~5.2% of SYRE's $7.7B market cap, a highly material signal. The dominant seller (Fairmount) alone sold $399.7M.
Risk Factors
- Fairmount's sale may be fund-level rebalancing, not company-specific bearishness
- CFO Burrows' sale is small and likely liquidity-driven after option exercise
- No insider buying to offset the selling signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SYRE-1782523946746 |
Track record
36 reports on SYRE
8 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers